TICKERNERD
Menu
BCRXBCRXHealthcare · Drug Manufacturers - Specialty & Generic

BCRX Stock Forecast: BioCryst Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$7.95
−1.85% on the day

The 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. hold a median 12-month price target of $17 — +113.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.1B
Ticker Nerd rank
88 / 100
Median analyst target
$17
Analysts covering
11
Revenue$218.3M+33.6% y/y
Operating income$98.5M
Net income$78.4M
Free cash flow$104.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
−20.2%
YTD
+1.9%
1Y
+13.2%
From 52W high
−28.4%
From 52W low
+27.4%
$6
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BCRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioCryst Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
88 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Accruals
91
Volatility
89
Quality
81
Revisions
78
Growth
75
Momentum
53
Size
35
Issuance
10

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BCRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26BCRXHigh $32Median $17Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $11Median $17High $32

The green dot is the last close — the median target sits +113.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
30 Sept 2026JP MorganMaintainsNeutral$12 → $13
10 Sept 2026RBC CapitalDowngradeSector Perform—
10 Sept 2026RBC CapitalDowngradeSector Perform$13 → $11
8 Sept 2026NeedhamReiteratesBuy—
8 Sept 2026NeedhamReiteratesBuy$16
6 Aug 2026RBC CapitalMaintainsOutperform$14 → $13
6 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026WedbushMaintainsOutperform—
6 Aug 2026WedbushMaintainsOutperform$21 → $20
13 July 2026JP MorganReinstatesNeutral$12
7 July 2026RBC CapitalMaintainsOutperform$13 → $14
7 July 2026RBC CapitalMaintainsOutperform—
30 June 2026Cantor FitzgeraldMaintainsOverweight—
30 June 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026CitizensMaintainsMarket Outperform—
7 May 2026WedbushMaintainsOutperform—
6 May 2026NeedhamMaintainsBuy—
30 Jan 2026RBC CapitalMaintainsOutperform—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
5 Nov 2025CitizensMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BCRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BCRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, BioCryst Pharmaceuticals, Inc. returned +13.2% against +17.3% for the S&P 500, dividends included.

BCRX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26BCRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BCRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+31.9%
Analysts raising
1
Analysts cutting
1
Fundamentals

BioCryst Pharmaceuticals, Inc. (BCRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.0×

Cheaper than 63% of US stocks

Price / sales
2.2×

Cheaper than 49% of US stocks

Price / book
−4.6×

Cheaper than 97% of US stocks

EV / EBITDA
5.9×

Cheaper than 51% of US stocks

Growth & margins
Revenue growth (YoY)
33.6%

Higher than 80% of US stocks

Earnings growth (YoY)
1441.7%

Higher than 98% of US stocks

Gross margin
98.2%

Higher than 99% of US stocks

Operating margin
45.1%

Higher than 94% of US stocks

Net margin
−40.9%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−221.4%

Higher than 7% of US stocks

Return on assets
52.9%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioCryst Pharmaceuticals, Inc. (BCRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioCryst Pharmaceuticals, Inc. has a market value of $2.1B and an enterprise value of $2.6B.

  • Revenue in the twelve months to 30 June 2026: $940.6M. The latest quarter grew 33.6% year on year.

  • Net income over the same four quarters: −$384.7M, a −40.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.50.

  • Free cash flow in the twelve months to 30 June 2026: $373.4M.

  • Shares outstanding: 255.3M.

  • Trailing P/E: 7.0×; forward P/E: 8.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • BioCryst Pharmaceuticals, Inc. employs 435 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

BCRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BCRXBioCryst Pharmaceuticals, Inc.$2.1B
88
PRGOPerrigo Co. Plc$1.9B
77
TRLVTrulieve Cannabis Corp.$2.0B
89
XERSXeris Biopharma Holdings, Inc.$1.8B
83
BHCBausch Health Cos., Inc.$2.2B
98
PBHPrestige Consumer Healthcare, Inc.$2.2B
60
LQDALiquidia Corp.$2.3B
70

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioCryst Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BCRX news & analysis

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

GlobeNewsWire · 5 Oct 2026positive

BioCryst Pharmaceuticals announced the formation of a Scientific Advisory Board (SAB) comprising seven scientific and industry leaders with expertise in rare disease research and drug development. The move supports the company's shift toward a more disciplined R&D model centered on external innovation.

Why it matters — A BCRX watcher would care because the new advisory board brings experienced scientific and industry leadership to help guide the company's rare disease pipeline as it evolves toward a more externally focused R&D strategy.

Biopharma Stock With Layers of Technical Support in Place

Schaeffers Research · 21 Sept 2026neutral

After a recent pullback, BioCryst Pharmaceuticals (NASDAQ:BCRX) bounced off the $8 level and reclaimed its 320-day moving average. Both levels have been key lines of pressure and support for the stock, suggesting multiple layers of technical support are now in place.

Why it matters — BCRX watchers would care because the stock's recovery off the $8 level and its move back above the 320-day moving average point to important technical levels that could inform how the shares behave going forward.

BioCryst Eyes $1B Rare-Disease Future Through External Innovation

MarketBeat · 19 Sept 2026positive

Newly appointed BioCryst Pharmaceuticals CEO Charlie Gayer said at a Morgan Stanley event that the company is shifting its strategy toward external innovation to expand beyond its ORLADEYO hereditary angioedema franchise, targeting a $1 billion rare-disease future.

Why it matters — BCRX watchers would care because the company is signaling a strategic pivot beyond its core ORLADEYO product, which could shape its future growth and pipeline direction.

4 Biotech Stocks to Watch as Potential Takeover Targets

Zacks Investment Research · 18 Sept 2026neutral

Zacks Investment Research reports that biotech M&A activity is surging in 2026, placing BioCryst Pharmaceuticals (BCRX) on a watchlist of potential takeover targets alongside ABVX, IOVA, and VKTX. Drugmakers are reportedly seeking late-stage and commercial assets.

Why it matters — BCRX watchers would care because the item signals that the company is being highlighted as a potential acquisition target amid a wave of biotech dealmaking in 2026.

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

BioCryst Pharmaceuticals presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with the session made available as a transcript. The presentation covered the company's participation at the investor event.

Why it matters — BCRX watchers would be interested in the conference presentation as a public platform for the company to communicate its current business position and strategic outlook to investors and analysts.

FAQ

Frequently asked questions about BCRX stock

What is the BCRX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. have a median 12-month price target of $17, with estimates ranging from $11 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BCRX stock a buy right now?

Of the 11 analysts covering BioCryst Pharmaceuticals, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioCryst Pharmaceuticals, Inc. 88 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCRX?

As at 6 Oct 2026, BioCryst Pharmaceuticals, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will BCRX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +113.8% from the last close, and Ticker Nerd's factor model ranks BioCryst Pharmaceuticals, Inc. 88 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BCRX stock forecast for 2030?

No analyst covering BioCryst Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $32 over the next 12 months.

How has BCRX stock performed over the past year?

BioCryst Pharmaceuticals, Inc. returned +13.2% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioCryst Pharmaceuticals, Inc. do?

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE).

What is the latest news on BCRX?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth". BioCryst Pharmaceuticals announced the formation of a Scientific Advisory Board (SAB) comprising seven scientific and industry leaders with expertise in rare disease research and drug development. The move supports the company's shift toward a more disciplined R&D model centered on external innovation.

Company

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE). Its commercial portfolio is centered on ORLADEYO, an oral therapy used to help prevent HAE attacks, alongside RAPIVAB, an injectable antiviral medicine used in the treatment of influenza in the United States. The company also supports a broader rare-disease pipeline built around oral small-molecule and protein-based therapeutics designed to address difficult-to-treat conditions. BioCryst Pharmaceuticals serves patients, physicians, and healthcare systems through specialty pharmaceutical products aimed at chronic disease management and acute treatment needs. Headquartered in Durham, North Carolina, BioCryst Pharmaceuticals plays a focused role in the rare-disease market by combining commercial medicines with targeted drug development expertise.

CEO Mr. Charles K. Gayer · 435 employees · United States · https://www.biocryst.com